Hepatocellular Carcinoma
Advertisement
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Ablative therapy is an important treatment option for achieving a cancer-free state as HCC rates continue to rise.
Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates.
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
A new report detailed the results of the LEAP-002 study following 12 months of additional follow-up.
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
Dr. Julien Calderaro explains the potential of AI to serve as a biomarker of sensitivity to atezolizumab plus bevacizumab.
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
The CRAFITY score is based on C-reactive protein and serum AFP in immunotherapy to predict prognosis in patients with HCC..
The combination can serve as a potential first-line treatment for patients aged 80 years or older.
Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO.
Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.
According to a recent study, DAAs remain underutilized in patients with HCV-related HCC, despite improved survival outcomes.
Dr. Fatema Tashrifwala explains new research highlighting the effectiveness of TACE plus camrelizumab.
Investigators determined that progression-free survival for patients who received TACE plus camrelizumab was 6.2 months.
Investigators also researched the possibility that AI could predict progression-free survival.
Researchers analyzed the effects of the 2015 MELD except policy change on liver transplants for patients with HCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.